论文部分内容阅读
在体外受精－胚胎移植（ＩＶＦ－ＥＴ）周期中，应用长效促性腺激素释放激素激动剂（ｇｏ－ｎａｄｏｔｒｏｐｈｉｎｒｅｌｅａｓｉｎｇｈｏｒｍｏｎｅａｇｏｎｉｓｔ，ＧｎＲＨ－ａ）合用促性腺激素（ｇｏｎａｄｏｔｒｏｐｈｉｎ，Ｇｎ）治疗２６例顽固性多囊卵巢综合征患者并与其中１９例前次常规ＩＶＦ－ＥＴ方案治疗的结果相比较。结果：①长效ＧｎＲＨ激动剂治疗组受精率和妊娠率分别为７６．２％和３８．６％，有明显提高（Ｐ＜０．０５）。②用药２周后，子宫内膜厚度及卵巢面积明显缩小，用药第４周时，达最小值。③促黄体生成素（ＬＨ）、促卵泡生成素（ＦＳＨ）、睾丸酮（Ｔ）、雌二醇（Ｅ２）在用药１周后开始下降，至用药第４周达早卵泡期水平。结果提示：对于使用常规ＩＶＦ－ＥＴ方案过程中，曾发生卵巢过度刺激综合征或早熟ＬＨ峰以及使用外源性Ｇｎ６个周期无受孕的多囊卵巢综合征病人，长效ＧｎＲＨ联合Ｇｎ超排卵是较好的选择方案。
In the IVF-ET cycle, 26 cases of intractable polycystic ovary were treated with gonadotrophin (GnRH-a) and gonadotropin releasing hormone agonist (GnRH-a) Syndrome patients were compared with the results of 19 of the previous IVF-ET regimens. Results: ① The fertilization rate and pregnancy rate of long-acting GnRH agonist group were 76.2% and 38.6%, respectively, which were significantly increased (P <0.05). ② After 2 weeks of treatment, endometrial thickness and ovarian area were significantly reduced, reaching the minimum value at 4 weeks after treatment. The levels of LH, FSH, T and E2 began to decrease after one week of treatment, reaching the level of early follicular phase in the fourth week of the medication. The results suggest that long-acting GnRH in combination with Gn superovulation is associated with ovarian hyperstimulation syndrome or precocious LH peak and polycystic ovary syndrome patients who are exogenously Gn 6 cycles without conception during routine IVF-ET regimen Better choice.